Moderna is a biotechnology company and pioneer in mRNA medicine, focused on developing vaccines and therapeutics across infectious disease, oncology, and rare disease. The company currently markets three commercial products: Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine). In 2025, Moderna generated $1.9 billion in total revenue, primarily from COVID vaccine sales, while advancing a broader pipeline including individualized cancer therapies.
expected 2026-10-30
| Type | Subject | Detail | Quarter |
|---|---|---|---|
| topic_mention | MRNA | discussed Blockchain & Crypto | |
| topic_mention | MRNA | discussed Regulation | |
| topic_mention | MRNA | discussed Automotive | |
| topic_mention | MRNA | discussed Healthcare & Bio | |
| topic_mention | MRNA | discussed Capital Expenditure | |
| topic_mention | MRNA | discussed Supply Chain | |
| topic_mention | MRNA | discussed Regulation | |
| topic_mention | MRNA | discussed Automotive | |
| topic_mention | MRNA | discussed Healthcare & Bio | |
| topic_mention | MRNA | discussed Platform & Ecosystem | |
| guidance | MRNA | guided expect total revenue in 2025 to be in the range of $1.5 billion | |
| guidance | MRNA | guided expected to be approximately $1.1 billion | |
| guidance | MRNA | guided expect taxes to be negligible in 2025, and capital expenditures are projected to be approximately $400 million | |
| guidance | MRNA | guided expect to end 2025 with approximately $6 billion | |
| guidance | MRNA | guided forecast from $5.9 billion | |
| guidance | MRNA | guided guidance includes $0.9 billion | |
| outlook | MRNA | stated We expect taxes to be negligible in 2025, and capital expenditures are projected to be approximately $400 million | |
| outlook | MRNA | stated we expect to complete now by this summer | |
| outlook | MRNA | stated We expect to have more clarity on the pace of case accrual and potential readout timing later this year | |
| outlook | MRNA | stated We expect the potential for approval for M&A in 2028 |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-20 | 2025-12-31 | 0001682852-26-000033 | EDGAR | 95K words |
| 2025-02-21 | 2024-12-31 | 0001682852-25-000022 | EDGAR | 96K words |
| 2024-02-23 | 2023-12-31 | 0001682852-24-000015 | EDGAR | 97K words |
| 2023-02-24 | 2022-12-31 | 0001682852-23-000011 | EDGAR | — |
| 2022-02-25 | 2021-12-31 | 0001682852-22-000012 | EDGAR | — |
| 2021-02-26 | 2020-12-31 | 0001682852-21-000006 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-31 | 2026-06-30 | 0001682852-26-000150 | EDGAR | 22K words |
| 2025-11-06 | 2025-09-30 | 0001682852-25-000075 | EDGAR | 22K words |
| 2025-08-01 | 2025-06-30 | 0001682852-25-000044 | EDGAR | 22K words |
| 2025-05-01 | 2025-03-31 | 0001682852-25-000034 | EDGAR | 19K words |
| 2024-11-07 | 2024-09-30 | 0001682852-24-000060 | EDGAR | 21K words |
| 2024-08-01 | 2024-06-30 | 0001682852-24-000046 | EDGAR | 21K words |
| 2024-05-02 | 2024-03-31 | 0001682852-24-000027 | EDGAR | 18K words |
| 2023-11-03 | 2023-09-30 | 0001682852-23-000042 | EDGAR | 29K words |
| 2023-08-03 | 2023-06-30 | 0001682852-23-000027 | EDGAR | 26K words |
| 2023-05-04 | 2023-03-31 | 0001682852-23-000021 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001682852-22-000051 | EDGAR | — |
| 2022-08-03 | 2022-06-30 | 0001682852-22-000042 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-09-01 | 0001193125-26-378505 | EDGAR | 2K words |
| 2026-07-31 | 0001682852-26-000147 | EDGAR | 4K words |
| 2026-03-05 | 0001682852-26-000047 | EDGAR | 1K words |
| 2026-02-13 | 0001682852-26-000015 | EDGAR | 4K words |
| 2026-02-11 | 0001682852-26-000012 | EDGAR | 2K words |
| 2026-01-12 | 0001682852-26-000007 | EDGAR | 1K words |
| 2026-01-05 | 0001682852-26-000003 | EDGAR | 3K words |
| 2025-11-24 | 0001628280-25-053816 | EDGAR | 126K words |
| 2025-11-20 | 0001628280-25-053318 | EDGAR | 2K words |
| 2025-11-13 | 0001628280-25-052055 | EDGAR | 1K words |
89 total filings indexed. 61 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| Call Date | Quarter | Title |
|---|---|---|
| — | MRNA Earnings Call Transcript | |
| — | MRNA Earnings Call Transcript | |
| — | MRNA Earnings Call Transcript | |
| — | MRNA Earnings Call Transcript | |
| — | MRNA Earnings Call Transcript | |
| — | Q1 FY3025 | MRNA Q1 FY3025 Earnings Call Transcript |
| — | Q4 FY2025 | MRNA Q4 FY2025 Earnings Call Transcript |
Access full transcripts via API (JSON) — includes speakers, key metrics, competitive mentions, and origin provenance chain.
| CIK | 0001682852 |
| Ticker | MRNA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.modernatx.com |
| Listed | 2018-12-07 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MRNA (~200 tokens, structured JSON with cryptographic provenance)